Get notified when QDEL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Material Weakness (improved) — Material weakness in internal controls over financial reporting remediated; disclosure controls now deemed effective as of June 28, 2026.
QuidelOrtho Q2 2026: Net loss narrows 64% to -$92.9M on 2.8% revenue growth
Filed August 7, 2026 · Period ending June 28, 2026 · Compared to 10-Q Aug 6, 2025 · ~1 min read
Key Changes
-
high
Revenue rose 2.8% to $630.9M.
Key Financials / MD&A view on EDGAR → -
high
Material weakness in internal controls remediated; disclosure controls now effective after ERP migration completed. Previously ineffective controls cited material weaknesses as of June 2025.
Controls & Procedures verify on EDGAR → -
high
Company now incurring incremental tariff costs on parts, materials, and shipping; offsetting through supply-chain adjustments. Section 232 medical-equipment investigation (Sept 2025) and Section 301 forced-labor tariffs (July 2026) could materially affect costs.
MD&A: Tariffs verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (GREE 10-Q) is open in full — no account needed.
Partner
Trade QDEL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 19, 2026 · How we verify